Hyperexcitability and translational phenotypes in a preclinical mouse model of SYNGAP1-Related Intellectual Disability
Authors:
- Jill SilvermanJSJill Silverman
- Emily SmithESEmily Smith
- Roy Ben-ShalomRBRoy Ben-Shalom
- Kiya JacksonKJKiya Jackson
- Cesar CanalesCCCesar Canales
- Alex NordANAlex Nord
- Darlene RahbarianDRDarlene Rahbarian
Preprint
- 19 March 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Disruption of SYNGAP1 directly causes a genetically identifiable neurodevelopmental disorder (NDD) called SYNGAP1-related intellectual disability (SRID). Without functional SynGAP1 protein, individuals are developmentally delayed and have prominent features of intellectual disability, motor impairments, and epilepsy. Over the past two decades, there have been numerous discoveries indicting the critical role of Syngap1. Several rodent models with a loss of Syngap1 have been engineered identifying precise roles in neuronal structure and function, as well as key biochemical pathways key for synapse integrity. Homozygous loss of Syngap1 is lethal. Heterozygous mutations of Syngap1 result in a broad range of behavioral phenotypes. Our in vivo functional data, using the mouse model from the Huganir laboratory, corroborated earlier reported behaviors including robust hyperactivity and deficits in learning and memory in young adults. In extension, we report impairments in slow wave sleep, a critical component of the domain of sleep. We characterized Syngap1+/- mice by using neurophysiology collected with wireless, telemetric electroencephalography (EEG). Syngap1+/- mice also exhibited elevated spiking events and spike trains, in addition to elevated power, most notably in the delta frequency band. For the first time, we illustrated how primary neurons from Syngap1+/- mice function and display increased network firing activity, greater bursts, and shorter inter-burst intervals between peaks by employing high density microelectrode arrays (HD-MEA). Our reported data bridge in-vitro electrophysiological neuronal activity and function with in vivo neurophysiological brain activity and function. These data elucidate quantitative, translational biomarkers in vivo and in vitro that can be utilized for the development of and efficacy assessment of targeted treatments for SRID.Keywords
All Related Versions
- Version 1, 2024-03-19, Research Square
- Published version: Translational Psychiatry, 14 (1), 1.
This publication has 69 references indexed in Scilit:
- Gait as a quantitative translational outcome measure in Angelman syndromeAutism Research, 2022
- Delta power robustly predicts cognitive function in Angelman syndromeAnnals of Clinical and Translational Neurology, 2021
- Low-Dose Perampanel Rescues Cortical Gamma Dysregulation Associated With Parvalbumin Interneuron GluA2 Upregulation in Epileptic Syngap1+/− MiceBiological Psychiatry, 2020
- Model organism development and evaluation for late‐onset Alzheimer's disease: MODEL‐ADAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2020
- Prenatal treatment path for angelman syndrome and other neurodevelopmental disordersAutism Research, 2019
- Comprehensive behavioral analysis of heterozygous Syngap1 knockout miceNeuropsychopharmacology Reports, 2019
- Syngap1 Haploinsufficiency Damages a Postnatal Critical Period of Pyramidal Cell Structural Maturation Linked to Cortical Circuit AssemblyBiological Psychiatry, 2015
- S‐adenosylmethionine and S‐adenosylhomocysteine in plasma and cerebrospinal fluid in Rett syndrome and the effect of folinic acid supplementationJournal of Inherited Metabolic Disease, 2013
- Sociability and motor functions in Shank1 mutant miceBrain Research, 2011
- Genetic Approaches to Studying Mouse Models of Human Seizure Disorders2004